PubRank

Madhukar H Trivedi

Author PubWeight™ 307.43‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 The 16-Item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biol Psychiatry 2003 13.60
2 Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 2006 12.41
3 Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design. Control Clin Trials 2004 6.64
4 Remissions in maternal depression and child psychopathology: a STAR*D-child report. JAMA 2006 6.26
5 Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N Engl J Med 2006 6.00
6 Background and rationale for the sequenced treatment alternatives to relieve depression (STAR*D) study. Psychiatr Clin North Am 2003 5.05
7 Exercise treatment for depression: efficacy and dose response. Am J Prev Med 2005 4.99
8 Difference in treatment outcome in outpatients with anxious versus nonanxious depression: a STAR*D report. Am J Psychiatry 2008 4.98
9 Tranylcypromine versus venlafaxine plus mirtazapine following three failed antidepressant medication trials for depression: a STAR*D report. Am J Psychiatry 2006 3.90
10 Report by the ACNP Task Force on response and remission in major depressive disorder. Neuropsychopharmacology 2006 3.80
11 The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol 2008 3.65
12 Combining medications to enhance depression outcomes (CO-MED): acute and long-term outcomes of a single-blind randomized study. Am J Psychiatry 2011 3.34
13 An evaluation of the quick inventory of depressive symptomatology and the hamilton rating scale for depression: a sequenced treatment alternatives to relieve depression trial report. Biol Psychiatry 2005 3.03
14 A comparison of mirtazapine and nortriptyline following two consecutive failed medication treatments for depressed outpatients: a STAR*D report. Am J Psychiatry 2006 2.90
15 Cognitive therapy versus medication in augmentation and switch strategies as second-step treatments: a STAR*D report. Am J Psychiatry 2007 2.84
16 Children of depressed mothers 1 year after remission of maternal depression: findings from the STAR*D-Child study. Am J Psychiatry 2011 2.58
17 Variation in the gene encoding the serotonin 2A receptor is associated with outcome of antidepressant treatment. Am J Hum Genet 2006 2.55
18 Children of depressed mothers 1 year after the initiation of maternal treatment: findings from the STAR*D-Child Study. Am J Psychiatry 2008 2.42
19 A comparison of lithium and T(3) augmentation following two failed medication treatments for depression: a STAR*D report. Am J Psychiatry 2006 2.21
20 Association between major depressive episodes in patients with chronic kidney disease and initiation of dialysis, hospitalization, or death. JAMA 2010 2.16
21 The STAR*D Project results: a comprehensive review of findings. Curr Psychiatry Rep 2007 2.08
22 Evidence-based recommendations for the prescription of exercise for major depressive disorder. J Psychiatr Pract 2013 2.04
23 Selecting among second-step antidepressant medication monotherapies: predictive value of clinical, demographic, or first-step treatment features. Arch Gen Psychiatry 2008 1.92
24 Self-rated global measure of the frequency, intensity, and burden of side effects. J Psychiatr Pract 2006 1.89
25 The pattern of sensory processing abnormalities in autism. Autism 2006 1.83
26 Gender differences in depression: findings from the STAR*D study. J Affect Disord 2005 1.80
27 Effect of age at onset on the course of major depressive disorder. Am J Psychiatry 2007 1.78
28 Texas Children's Medication Algorithm Project: update from Texas Consensus Conference Panel on Medication Treatment of Childhood Major Depressive Disorder. J Am Acad Child Adolesc Psychiatry 2007 1.78
29 What did STAR*D teach us? Results from a large-scale, practical, clinical trial for patients with depression. Psychiatr Serv 2009 1.77
30 Prevalence and clinical correlates of irritability in major depressive disorder: a preliminary report from the Sequenced Treatment Alternatives to Relieve Depression study. J Clin Psychiatry 2005 1.70
31 Prospective trial of equine-assisted activities in autism spectrum disorder. Altern Ther Health Med 2011 1.69
32 Predictors of attrition during initial (citalopram) treatment for depression: a STAR*D report. Am J Psychiatry 2007 1.67
33 Inverse association between physical inactivity and mental health in men and women. Med Sci Sports Exerc 2006 1.66
34 Measurement-based care in psychiatric practice: a policy framework for implementation. J Clin Psychiatry 2011 1.65
35 Does psychosocial functioning improve independent of depressive symptoms? A comparison of nefazodone, psychotherapy, and their combination. Biol Psychiatry 2002 1.65
36 Clinical correlates and symptom patterns of anxious depression among patients with major depressive disorder in STAR*D. Psychol Med 2004 1.64
37 The Montgomery Asberg and the Hamilton ratings of depression: a comparison of measures. Eur Neuropsychopharmacol 2006 1.58
38 Response to a selective serotonin reuptake inhibitor (citalopram) in major depressive disorder with melancholic features: a STAR*D report. J Clin Psychiatry 2008 1.57
39 Children of currently depressed mothers: a STAR*D ancillary study. J Clin Psychiatry 2006 1.57
40 Texas Medication Algorithm Project, phase 3 (TMAP-3): rationale and study design. J Clin Psychiatry 2003 1.56
41 Aripiprazole augmentation in major depressive disorder: a double-blind, placebo-controlled study in patients with inadequate response to antidepressants. CNS Spectr 2009 1.55
42 The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) Study: Outcomes from the 2-year and combined maintenance phases. J Clin Psychiatry 2007 1.54
43 Association between a functional serotonin transporter promoter polymorphism and citalopram treatment in adult outpatients with major depression. Arch Gen Psychiatry 2007 1.53
44 Association between treatment-emergent suicidal ideation with citalopram and polymorphisms near cyclic adenosine monophosphate response element binding protein in the STAR*D study. Arch Gen Psychiatry 2007 1.53
45 Comorbid psychiatric disorders in depressed outpatients: demographic and clinical features. J Affect Disord 2005 1.49
46 The impact of nonclinical factors on care use for patients with depression: a STAR*D report. CNS Neurosci Ther 2009 1.49
47 Self-reported depressive symptom measures: sensitivity to detecting change in a randomized, controlled trial of chronically depressed, nonpsychotic outpatients. Neuropsychopharmacology 2005 1.47
48 Impaired delay and trace eyeblink conditioning performance in major depressive disorder. J Affect Disord 2005 1.45
49 Diurnal mood variation in outpatients with major depressive disorder: implications for DSM-V from an analysis of the Sequenced Treatment Alternatives to Relieve Depression Study data. J Clin Psychiatry 2007 1.45
50 Effect of 11 September 2001 terrorist attacks in the USA on suicide in areas surrounding the crash sites. Br J Psychiatry 2010 1.45
51 Sensory correlations in autism. Autism 2007 1.44
52 The current crisis of confidence in antidepressants. J Clin Psychiatry 2011 1.44
53 STAR*D: revising conventional wisdom. CNS Drugs 2009 1.41
54 Prevention of recurrent episodes of depression with venlafaxine ER in a 1-year maintenance phase from the PREVENT Study. J Clin Psychiatry 2007 1.40
55 Comparative effectiveness of biomarkers and clinical indicators for predicting outcomes of SSRI treatment in Major Depressive Disorder: results of the BRITE-MD study. Psychiatry Res 2009 1.40
56 Complementary and alternative medicine in major depressive disorder: the American Psychiatric Association Task Force report. J Clin Psychiatry 2010 1.38
57 Can phase III trial results of antidepressant medications be generalized to clinical practice? A STAR*D report. Am J Psychiatry 2009 1.38
58 Treatment-resistant depression. J Clin Psychiatry 2006 1.37
59 Cognitive behavioral analysis system of psychotherapy and brief supportive psychotherapy for augmentation of antidepressant nonresponse in chronic depression: the REVAMP Trial. Arch Gen Psychiatry 2009 1.35
60 Prevention of missing data in clinical research studies. Biol Psychiatry 2006 1.32
61 Association between bipolar spectrum features and treatment outcomes in outpatients with major depressive disorder. Arch Gen Psychiatry 2010 1.29
62 Pharmacogenetic analysis of genes implicated in rodent models of antidepressant response: association of TREK1 and treatment resistance in the STAR(*)D study. Neuropsychopharmacology 2008 1.29
63 A randomized, double-blind, placebo-controlled study of the efficacy and safety of vortioxetine 10 mg and 20 mg in adults with major depressive disorder. J Clin Psychiatry 2015 1.28
64 Primary versus specialty care outcomes for depressed outpatients managed with measurement-based care: results from STAR*D. J Gen Intern Med 2008 1.28
65 Suicidality and risk of suicide--definition, drug safety concerns, and a necessary target for drug development: a consensus statement. J Clin Psychiatry 2010 1.27
66 Concurrent anxiety and substance use disorders among outpatients with major depression: clinical features and effect on treatment outcome. Drug Alcohol Depend 2008 1.24
67 What predicts attrition in second step medication treatments for depression?: a STAR*D Report. Int J Neuropsychopharmacol 2008 1.23
68 A randomized, double-blind, placebo-controlled study of the efficacy and safety of 2 doses of vortioxetine in adults with major depressive disorder. J Clin Psychiatry 2015 1.23
69 Defining and measuring functional recovery from depression. CNS Drugs 2010 1.21
70 The STAR*D study: treating depression in the real world. Cleve Clin J Med 2008 1.20
71 Sex differences in depression symptoms in treatment-seeking adults: confirmatory analyses from the Sequenced Treatment Alternatives to Relieve Depression study. Compr Psychiatry 2008 1.20
72 Major depression symptoms in primary care and psychiatric care settings: a cross-sectional analysis. Ann Fam Med 2007 1.19
73 Effectiveness of a quantitative electroencephalographic biomarker for predicting differential response or remission with escitalopram and bupropion in major depressive disorder. Psychiatry Res 2009 1.18
74 Insomnia in patients with depression: a STAR*D report. CNS Spectr 2010 1.18
75 Chronic depression: medication (nefazodone) or psychotherapy (CBASP) is effective when the other is not. Arch Gen Psychiatry 2005 1.17
76 What clinical and symptom features and comorbid disorders characterize outpatients with anxious major depressive disorder: a replication and extension. Can J Psychiatry 2006 1.16
77 The effects of psychotherapy, nefazodone, and their combination on subjective assessment of disturbed sleep in chronic depression. Sleep 2003 1.14
78 Residual symptoms in depressed outpatients who respond by 50% but do not remit to antidepressant medication. J Clin Psychopharmacol 2011 1.14
79 Health-related quality of life in depression: a STAR*D report. Ann Clin Psychiatry 2010 1.13
80 Comparison of self-report and clinician ratings on two inventories of depressive symptomatology. Psychiatr Serv 2006 1.12
81 Chronic forms of major depression are still undertreated in the 21st century: systematic assessment of 801 patients presenting for treatment. J Affect Disord 2008 1.12
82 Remission of maternal depression: relations to family functioning and youth internalizing and externalizing symptoms. J Clin Child Adolesc Psychol 2008 1.11
83 Clinical vs. self-report versions of the quick inventory of depressive symptomatology in a public sector sample. J Psychiatr Res 2006 1.11
84 Epidemiology of nonfatal deliberate self-harm in the United States as described in three medical databases. Suicide Life Threat Behav 2006 1.10
85 Early adversity in chronic depression: clinical correlates and response to pharmacotherapy. Depress Anxiety 2009 1.10
86 Clinical correlates of the worsening or emergence of suicidal ideation during SSRI treatment of depression: an examination of citalopram in the STAR*D study. J Affect Disord 2009 1.08
87 The DOSE study: a clinical trial to examine efficacy and dose response of exercise as treatment for depression. Control Clin Trials 2002 1.08
88 Does comorbid substance use disorder impair recovery from major depression with SSRI treatment? An analysis of the STAR*D level one treatment outcomes. Drug Alcohol Depend 2009 1.06
89 Clinical differences among depressed patients with and without a history of suicide attempts: findings from the STAR*D trial. J Affect Disord 2006 1.05
90 Sulfhydryl-reactive metals in autism. J Toxicol Environ Health A 2007 1.05
91 Income and attrition in the treatment of depression: a STAR*D report. Depress Anxiety 2009 1.05
92 A psychometric evaluation of the CDRS and MADRS in assessing depressive symptoms in children. J Am Acad Child Adolesc Psychiatry 2007 1.04
93 Identifying predictors, moderators, and mediators of antidepressant response in major depressive disorder: neuroimaging approaches. Am J Psychiatry 2015 1.04
94 Sex differences in response to citalopram: a STAR*D report. J Psychiatr Res 2008 1.03
95 Concordance between clinician and patient ratings as predictors of response, remission, and recurrence in major depressive disorder. J Psychiatr Res 2010 1.03
96 Prenatal depression in women hospitalized for obstetric risk. J Clin Psychiatry 2008 1.02
97 Clinical features of depressed outpatients with and without co-occurring general medical conditions in STAR*D. Gen Hosp Psychiatry 2004 1.01
98 Remission of maternal depression and child symptoms among single mothers: a STAR*D-Child report. Soc Psychiatry Psychiatr Epidemiol 2007 1.01
99 Differential effects of nefazodone and cognitive behavioral analysis system of psychotherapy on insomnia associated with chronic forms of major depression. J Clin Psychiatry 2002 1.01
100 Psychometric evaluation of the Snaith-Hamilton pleasure scale in adult outpatients with major depressive disorder. Int Clin Psychopharmacol 2010 1.00
101 Association of polymorphisms in genes regulating the corticotropin-releasing factor system with antidepressant treatment response. Arch Gen Psychiatry 2010 1.00
102 Texas Medication Algorithm Project, phase 3 (TMAP-3): clinical results for patients with a history of mania. J Clin Psychiatry 2003 0.99
103 The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) study: outcomes from the acute and continuation phases. Biol Psychiatry 2007 0.99
104 Inflammation, obesity, and metabolic syndrome in depression: analysis of the 2009-2010 National Health and Nutrition Examination Survey (NHANES). J Clin Psychiatry 2014 0.99
105 Do atypical features affect outcome in depressed outpatients treated with citalopram? Int J Neuropsychopharmacol 2009 0.98
106 Suicidality and risk of suicide--definition, drug safety concerns, and a necessary target for drug development: a brief report. J Clin Psychiatry 2010 0.98
107 Effects of serum Brain Derived Neurotrophic Factor on exercise augmentation treatment of depression. J Psychiatr Res 2011 0.97
108 Agomelatine in the treatment of major depressive disorder: an 8-week, multicenter, randomized, placebo-controlled trial. J Clin Psychiatry 2010 0.97
109 Faster remission of chronic depression with combined psychotherapy and medication than with each therapy alone. J Consult Clin Psychol 2008 0.97
110 Examining the efficacy of adjunctive aripiprazole in major depressive disorder: a pooled analysis of 2 studies. Prim Care Companion J Clin Psychiatry 2008 0.97
111 Symptom features of postpartum depression: are they distinct? Depress Anxiety 2008 0.97
112 Sociodemographic, clinical, and treatment characteristics associated with worsened depression during treatment with citalopram: results of the NIMH STAR(*)D trial. Depress Anxiety 2009 0.95
113 Depressive symptoms and metabolic syndrome in preventive healthcare: the Cooper Center longitudinal study. Metab Syndr Relat Disord 2010 0.95
114 Psychometric properties of the Quick Inventory of Depressive Symptomatology in adolescents. Int J Methods Psychiatr Res 2010 0.95
115 Pain in depression: STAR*D study findings. J Psychosom Res 2007 0.94
116 Cognitive-behavioral analysis system of psychotherapy as a maintenance treatment for chronic depression. J Consult Clin Psychol 2004 0.94
117 Family history of mood disorder and characteristics of major depressive disorder: a STAR*D (sequenced treatment alternatives to relieve depression) study. J Psychiatr Res 2006 0.93
118 Acceptability of second-step treatments to depressed outpatients: a STAR*D report. Am J Psychiatry 2007 0.93
119 Characteristics of insured and noninsured outpatients with depression in STAR(*)D. Psychiatr Serv 2005 0.93
120 Strategies to enhance the therapeutic efficacy of antidepressants: targeting residual symptoms. Expert Rev Neurother 2009 0.93
121 Suicide risk management for the sequenced treatment alternatives to relieve depression study: applied NIMH guidelines. J Psychiatr Res 2004 0.93
122 The history and current state of antidepressant clinical trial design: a call to action for proof-of-concept studies. J Clin Psychiatry 2008 0.92
123 Making clinicians lives easier: guidance on use of the QIDS self-report in place of the MADRS. J Affect Disord 2006 0.92
124 Abnormal brain response to cholinergic challenge in chronic encephalopathy from the 1991 Gulf War. Psychiatry Res 2009 0.92
125 Are depressed outpatients with and without a family history of substance use disorder different? A baseline analysis of the STAR*D cohort. J Clin Psychiatry 2007 0.91
126 Decline in cardiorespiratory fitness and odds of incident depression. Am J Prev Med 2012 0.91
127 Efficacy of bupropion and the selective serotonin reuptake inhibitors in the treatment of anxiety symptoms in major depressive disorder: a meta-analysis of individual patient data from 10 double-blind, randomized clinical trials. J Psychiatr Res 2007 0.91
128 Safety and Tolerability of Adjunctive Aripiprazole in Major Depressive Disorder: A Pooled Post Hoc Analysis (studies CN138-139 and CN138-163). Prim Care Companion J Clin Psychiatry 2009 0.91
129 Measurement-based care for unipolar depression. Curr Psychiatry Rep 2011 0.90
130 A Comparison of the QIDS-C16, QIDS-SR16, and the MADRS in an Adult Outpatient Clinical Sample. CNS Spectr 2010 0.90
131 Major depressive disorder and comorbid cardiac disease: is there a depressive subtype with greater cardiovascular morbidity? Results from the STAR*D study. Psychosomatics 2007 0.90
132 Predictors of attrition with buprenorphine/naloxone treatment in opioid dependent youth. Addict Behav 2012 0.90
133 Electronic source materials in clinical research: acceptability and validity of symptom self-rating in major depressive disorder. J Psychiatr Res 2007 0.89
134 A pilot study of an electronic, adolescent version of the quick inventory of depressive symptomatology. J Clin Psychiatry 2007 0.89
135 Crisis of confidence: antidepressant risk versus benefit. J Clin Psychiatry 2011 0.89
136 Depression treatment in patients with general medical conditions: results from the CO-MED trial. Ann Fam Med 2012 0.89
137 Does provider adherence to a treatment guideline change clinical outcomes for patients with bipolar disorder? Results from the Texas Medication Algorithm Project. Psychol Med 2005 0.89
138 Baseline depression severity as a predictor of single and combination antidepressant treatment outcome: results from the CO-MED trial. Eur Neuropsychopharmacol 2011 0.88
139 Efficacy of porcine secretin in children with autism and pervasive developmental disorder. J Autism Dev Disord 2002 0.88
140 Exercise in the treatment of depression. Curr Psychiatry Rep 2009 0.88
141 Rationale and methods for site selection for a trial using a novel intervention to treat stimulant abuse. Contemp Clin Trials 2011 0.88
142 Item Response Analysis of the Inventory of Depressive Symptomatology. Neuropsychiatr Dis Treat 2006 0.87
143 Folate and unipolar depression. J Altern Complement Med 2008 0.87
144 Randomized, placebo-controlled trial of nefazodone maintenance treatment in preventing recurrence in chronic depression. Biol Psychiatry 2003 0.86
145 Family history of depression and therapeutic outcome: findings from STAR*D. J Clin Psychiatry 2008 0.86
146 Response to Zhang et al. (2005): loss-of-function mutation in tryptophan hydroxylase-2 identified in unipolar major depression. Neuron 45, 11-16. Neuron 2005 0.86
147 Assessing anxious features in depressed outpatients. Int J Methods Psychiatr Res 2011 0.86
148 An open pilot study of the combination of escitalopram and bupropion-SR for outpatients with major depressive disorder. J Psychiatr Pract 2008 0.86
149 Identifying risk for attrition during treatment for depression. Psychother Psychosom 2009 0.86
150 Telephone-based assessments to minimize missing data in longitudinal depression trials: a project IMPACTS study report. Contemp Clin Trials 2008 0.86
151 Predictors of attrition during one year of depression treatment: a roadmap to personalized intervention. J Psychiatr Pract 2009 0.85
152 Early adverse events and attrition in selective serotonin reuptake inhibitor treatment: a suicide assessment methodology study report. J Clin Psychopharmacol 2010 0.85
153 Influences of hormone-based contraception on depressive symptoms in premenopausal women with major depression. Psychoneuroendocrinology 2007 0.85
154 Functional connectivity of brain structures correlates with treatment outcome in major depressive disorder. Front Psychiatry 2011 0.85
155 Symptomatic and syndromal anxiety in chronic forms of major depression: effect of nefazodone, cognitive behavioral analysis system of psychotherapy, and their combination. J Clin Psychiatry 2002 0.85
156 Power of automated algorithms for combining time-line follow-back and urine drug screening test results in stimulant-abuse clinical trials. Am J Drug Alcohol Abuse 2011 0.85
157 Comparing venlafaxine extended release and fluoxetine for preventing the recurrence of major depression: results from the PREVENT study. J Psychiatr Res 2011 0.84
158 Olanzapine/fluoxetine combination in patients with treatment-resistant depression: rapid onset of therapeutic response and its predictive value for subsequent overall response in a pooled analysis of 5 studies. J Clin Psychiatry 2010 0.84
159 Do menopausal status and use of hormone therapy affect antidepressant treatment response? Findings from the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study. J Womens Health (Larchmt) 2013 0.84
160 Continuation treatment of chronic depression: a comparison of nefazodone, cognitive behavioral analysis system of psychotherapy, and their combination. Psychopharmacol Bull 2003 0.84
161 Factors predicting reduced antidepressant response: experience with the SNRI duloxetine in patients with major depression. Ann Clin Psychiatry 2008 0.84
162 Adherence to antidepressant combinations and monotherapy for major depressive disorder: a CO-MED report of measurement-based care. J Psychiatr Pract 2014 0.84
163 Treatment outcomes for older depressed patients with earlier versus late onset of first depressive episode: a Sequenced Treatment Alternatives to Relieve Depression (STAR*D) report. Am J Geriatr Psychiatry 2008 0.84
164 Developing a neuropsychiatric functional brain imaging test. Neurocase 2008 0.84
165 Assessing rates and predictors of tachyphylaxis during the prevention of recurrent episodes of depression with venlafaxine ER for two years (PREVENT) study. Psychopharmacol Bull 2009 0.83
166 Comparison of quality of life measures in a depressed population. J Nerv Ment Dis 2007 0.83
167 Reductions in stress and depressive symptoms in mothers of substance-exposed infants, participating in a psychosocial program. Matern Child Health J 2004 0.83
168 An empirical analysis of cost outcomes of the Texas Medication Algorithm Project. Psychiatr Serv 2006 0.83
169 Depression outcomes in psychiatric clinical practice: using a self-rated measure of depression severity. Psychiatr Serv 2011 0.83
170 Relationship between obesity and depression: characteristics and treatment outcomes with antidepressant medication. Psychosom Med 2013 0.82
171 Does the duration of index episode affect the treatment outcome of major depressive disorder? A STAR*D report. J Clin Psychiatry 2008 0.82
172 Effect of antidepressant medication treatment on suicidal ideation and behavior in a randomized trial: an exploratory report from the Combining Medications to Enhance Depression Outcomes Study. J Clin Psychiatry 2011 0.82
173 Rationale and design of the Chronic Kidney Disease Antidepressant Sertraline Trial (CAST). Contemp Clin Trials 2012 0.81
174 Consensus statement and research needs: the role of dopamine and norepinephrine in depression and antidepressant treatment. J Clin Psychiatry 2006 0.81
175 The influence of menopause status and postmenopausal use of hormone therapy on presentation of major depression in women. Menopause 2010 0.81
176 Quantitative EEG amplitude across REM sleep periods in depression: preliminary report. J Psychiatry Neurosci 2002 0.81
177 A randomized, double-blind, duloxetine-referenced study comparing efficacy and tolerability of 2 fixed doses of vortioxetine in the acute treatment of adults with MDD. Psychopharmacology (Berl) 2015 0.81
178 Long-term safety and tolerability of open-label aripiprazole augmentation of antidepressant therapy in major depressive disorder. Neuropsychiatr Dis Treat 2011 0.81
179 Fractional anisotropy changes after several weeks of daily left high-frequency repetitive transcranial magnetic stimulation of the prefrontal cortex to treat major depression. J ECT 2011 0.81
180 Implementation of the Texas Medication Algorithm Project patient and family education program. J Clin Psychiatry 2006 0.81
181 Changes in depressive symptoms and social functioning in the sequenced treatment alternatives to relieve depression study. J Nerv Ment Dis 2011 0.81
182 The impact of diabetes on depression treatment outcomes. Gen Hosp Psychiatry 2009 0.81
183 Antenatal depression: a rationale for studying exercise. Depress Anxiety 2010 0.81
184 Variation in catechol-O-methyltransferase is associated with duloxetine response in a clinical trial for major depressive disorder. Biol Psychiatry 2008 0.81
185 Neural correlates of successful response inhibition in unmedicated patients with late-life depression. Am J Geriatr Psychiatry 2012 0.81
186 Depressive Symptoms and Associated Clinical Characteristics in Outpatients Seeking Community-Based Treatment for Alcohol and Drug Problems. Subst Abus 2014 0.80
187 Factors associated with concomitant psychotropic drug use in the treatment of major depression: a STAR*D Report. CNS Spectr 2009 0.80
188 DATE: Depressed adolescents treated with exercise: Study rationale and design for a pilot study. Ment Health Phys Act 2009 0.80
189 Influence of sex and menopausal status on response, remission, and recurrence in patients with recurrent major depressive disorder treated with venlafaxine extended release or fluoxetine: analysis of data from the PREVENT study. J Clin Psychiatry 2014 0.80
190 Comorbidities and race/ethnicity among adults with stimulant use disorders in residential treatment. J Ethn Subst Abuse 2015 0.80
191 Brief report: depression and history of suicide attempts in adults with new-onset Type 2 Diabetes. Psychoneuroendocrinology 2013 0.80
192 A comparison of baseline sociodemographic and clinical characteristics between major depressive disorder patients with and without diabetes: a STAR*D report. J Affect Disord 2007 0.79
193 The relationship between adverse events during selective serotonin reuptake inhibitor treatment for major depressive disorder and nonremission in the suicide assessment methodology study. J Clin Psychopharmacol 2011 0.79
194 Quantitative electroencephalogram biomarkers for predicting likelihood and speed of achieving sustained remission in major depression: a report from the biomarkers for rapid identification of treatment effectiveness in major depression (BRITE-MD) trial. J Clin Psychiatry 2013 0.79
195 A psychometric evaluation of the clinician-rated Quick Inventory of Depressive Symptomatology (QIDS-C16) in patients with bipolar disorder. Int J Methods Psychiatr Res 2009 0.79
196 Effect of concurrent substance use disorder on the effectiveness of single and combination antidepressant medications for the treatment of major depression: an exploratory analysis of a single-blind randomized trial. Depress Anxiety 2012 0.79
197 Remission with venlafaxine extended release or selective serotonin reuptake inhibitors in depressed patients: a randomized, open-label study. Prim Care Companion CNS Disord 2011 0.79
198 Using algorithms and computerized decision support systems to treat major depression. J Clin Psychiatry 2011 0.79
199 Family history of completed suicide and characteristics of major depressive disorder: a STAR*D (sequenced treatment alternatives to relieve depression) study. J Affect Disord 2007 0.79
200 What are the clinical implications of new onset or worsening anxiety during the first two weeks of SSRI treatment for depression? Depress Anxiety 2011 0.79
201 Exercise for mood and anxiety disorders. J Clin Psychiatry 2007 0.78
202 The effectiveness of secretin in the management of autism. Expert Opin Pharmacother 2004 0.78
203 Exercise for mood and anxiety disorders. Prim Care Companion J Clin Psychiatry 2007 0.78
204 Clinicians' adherence to an algorithm for pharmacotherapy of depression in the Texas public mental health sector. Psychiatr Serv 2004 0.78
205 Biomarkers and the future of treatment for depression. Cerebrum 2012 0.78
206 A computerized decision support system for depression in primary care. Prim Care Companion J Clin Psychiatry 2009 0.78
207 The clinical relevance of self-reported premenstrual worsening of depressive symptoms in the management of depressed outpatients: a STAR*D report. J Womens Health (Larchmt) 2013 0.78
208 Voice response system to measure healthcare costs: a STAR*D report. Am J Manag Care 2009 0.78
209 Using measurement-based care with patient involvement to improve outcomes in depression. Prim Care Companion CNS Disord 2013 0.78
210 Prevalence and impact of obsessive-compulsive symptoms in depression: a STAR*D report. J Clin Psychiatry 2015 0.78
211 Randomized comparison of selective serotonin reuptake inhibitor (escitalopram) monotherapy and antidepressant combination pharmacotherapy for major depressive disorder with melancholic features: a CO-MED report. J Affect Disord 2011 0.77
212 Sexual function and satisfaction in the treatment of chronic major depression with nefazodone, psychotherapy, and their combination. J Clin Psychiatry 2002 0.77
213 Challenges and algorithm-guided treatment in major depressive disorder. J Clin Psychiatry 2011 0.77
214 Managing depressive disorders in patients with epilepsy. Psychiatry (Edgmont) 2007 0.77
215 Tiagabine in adult patients with generalized anxiety disorder: results from 3 randomized, double-blind, placebo-controlled, parallel-group studies. J Clin Psychopharmacol 2008 0.77
216 A review of quetiapine in combination with antidepressant therapy in patients with depression. Neuropsychiatr Dis Treat 2007 0.77
217 The impact of chronic depression on acute and long-term outcomes in a randomized trial comparing selective serotonin reuptake inhibitor monotherapy versus each of 2 different antidepressant medication combinations. J Clin Psychiatry 2012 0.76
218 Screening for depression in a diabetic outpatient population. Int J Psychiatry Clin Pract 2007 0.76
219 Feasible evidence-based strategies to manage depression in primary care. Curr Psychiatry Rep 2012 0.76
220 Use of treatment algorithms for depression. Prim Care Companion J Clin Psychiatry 2006 0.76
221 Effects of heart disease on depression treatment: results from the COMED study. Gen Hosp Psychiatry 2011 0.76
222 Diurnal mood variation in outpatients with major depressive disorder. Depress Anxiety 2009 0.76
223 Do depressed patients with diabetes experience more side effects when treated with CitalopramThan their counterparts without diabetes? a STAR*D study. Prim Care Companion J Clin Psychiatry 2009 0.75
224 Depression and pain: implications for symptomatic presentation and pharmacological treatments. Psychiatry (Edgmont) 2005 0.75
225 Response to Stanton, Reaburn, and Rosenbaum. J Psychiatr Pract 2013 0.75
226 Men and women from the STRIDE clinical trial: An assessment of stimulant abstinence symptom severity at residential treatment entry. Am J Addict 2015 0.75
227 Quetiapine XR monotherapy in major depressive disorder: a pooled analysis to assess the influence of baseline severity on efficacy. Int Clin Psychopharmacol 2013 0.75
228 Prognostic Utility of a Self-Reported Depression Questionnaire versus Clinician-Based Assessment on Renal Outcomes. Am J Nephrol 2016 0.75
229 Insured and non-insured depressed outpatients: how do they compare? Ann Clin Psychiatry 2007 0.75
230 Do geographic regions with higher suicide rates also have higher rates of nonfatal intentional self-harm? Suicide Life Threat Behav 2008 0.75
231 Release bias in accessing medical records in clinical trials: a STAR*D report. Int J Methods Psychiatr Res 2009 0.75
232 Moderators of antidepressant response in major depression. J Clin Psychiatry 2011 0.75
233 Performance improvement CME: algorithms and EMRs in depression. J Clin Psychiatry 2011 0.75
234 Death by Insulin: Management of Self-Harm and Suicide in Diabetes Management. Curr Diabetes Rev 2016 0.75
235 Opioid addiction screening tools for patients with chronic noncancer pain. Tex Med 2015 0.75
236 Sustaining practice change one year after completion of the national depression management leadership initiative. Psychiatr Serv 2013 0.75
237 Using moderator-based algorithms and electronic medical records to achieve optimal outcomes in depression. J Clin Psychiatry 2011 0.75
238 Datapoints: rates of nonfatal intentional self-harm in nine states, 2001. Psychiatr Serv 2006 0.75